Published online Aug 15, 2020. doi: 10.4239/wjd.v11.i8.322
Peer-review started: March 20, 2020
First decision: April 26, 2020
Revised: May 27, 2020
Accepted: June 14, 2020
Article in press: June 14, 2020
Published online: August 15, 2020
Processing time: 146 Days and 13 Hours
Core tip: Visceral adiposity and morbid obesity are risk factors for heart and kidney disease, configuring a cardiorenal syndrome. Adipose tissue results in hemodynamic and mechanical derangements in addition to activating neuro-humoral systems such as endothelial dysfunction, adipokines, renin-angiotensin-aldosterone, sympathetic nervous system, natriuretic peptides, inflammation, and oxidative stress. Obesity induces cardiac remodeling and fibrosis, leading to heart failure (HF). HF with preserved ejection fraction is characteristically linked to obesity. Hyperfiltration, increased glomerular capillary wall tension, podocyte dysfunction, and, finally, chronic kidney disease has been linked to obesity. Most of the new treatments for diabetes mellitus type 2, which have favorable cardiovascular outcomes, improve the cardiometabolic renal syndrome associated with obesity.
